1.0 CEUs
Depression and HIV
Module Description Designed for the HIV health care professional, this webinar will look at the clinical manifestation of depression and HIV, diagnostic criteria, etiology and physiology of depression's impact on health, and evidence-based interventions - including the prescribing and monitoring of psychotropic medications.
Credit Dates 11/01/2023 – 10/31/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.
This activity is supported by an independent educational grant from Gilead Sciences.
Credit Dates 11/01/2023 – 10/31/2024
Jointly provided by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine.
This activity is supported by an independent educational grant from Gilead Sciences.
Learning Objectives
- Examine the prevalence, differential diagnosis, socio-cultural contexts, prognosis, and associated traits of mental health and substance use disorders among people with HIV.
- Share the diagnostic criteria of the significant mental health and substance use disorders among people with HIV.
- Evaluate the etiology and physiological effects of mental health and substance use disorders among people with HIV.
- Outline how clinicians can utilize validated tools and resources to assess the mental status of people with HIV to determine the need for referral to a mental health provider for testing or treatment.
- Summarize evidence-based treatment interventions, prescribing, and monitoring best practices for mental health and substance use disorders for people with HIV.
Target Audience
This activity is intended for physicians, PAs, NPs, RNs, and pharmacists who are engaged in the care of people with HIV.
Estimated Time to Complete the Activity: 1 hour
PresentersDr. Karl Goodkin, MD, PhD, DLFAPA, FACPsych, FRSM
Chair, Department of Psychiatry
University of Texas Rio Grande Valley School of Medicine
Instructions for Credit
There are no fees for participating and receiving CME/CE credit for this activity.
Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from November 1, 2023 through October 31, 2024:
- Review the objectives and disclosures
- Study the educational content
- Visit https://www.paceducation.com/HIVMH1E
- Complete the activity evaluation
If you have questions regarding the certification of this activity, please contact PACE by visiting ttps://partnersed.com.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the American Academy of HIV Medicine. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-23-294-H02-P)
Type of Activity: Knowledge
Continuing Nursing Education The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours, 0.25 pharmacotherapy credits for APRN.
Disclosure of Conflict of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Dr. Goodkin receives research funding from Cipla Pharmaceuticals, Dr. Reddy's, ScieGen Pharmaceuticals and Boehringer Ingelheim.
Planners and Managers
The PACE planners and managers have nothing to disclose.
The Academy planners and managers have nothing to disclose.
Media: Internet
Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
